Perosphere, Daiichi Sankyo to test antidote to edoxaban

04/26/2013 | Pharmaceutical Business Review Online

Perosphere and Daiichi Sankyo have agreed to work together on a clinical trial that will assess the efficacy and safety of PER977, a drug being designed to reverse the anticoagulant effect of edoxaban, a factor Xa inhibitor. In preclinical testing, PER977 attached to heparins and factor Xa and IIa inhibitors but not to blood proteins.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Sr. Compliance Director Ethics and Compliance
Medtronic
Fridley, MN
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC